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Abstract Among the causes of secondary hypertension are a
group of disorders with a Mendelian inheritance pattern.
Recent advances in molecular biology have unveiled the
pathogenesis of hypertension in many of these conditions.
Remarkably, the mechanism in every case has proved to be
upregulation of sodium (Na) reabsorption in the distal
nephron, with accompanying expansion of extracellular
volume. In one group, the mutations involve the Na-transport
machinery in distal tubule cells themselves: the distal
convoluted tubule (DCT) cell and the principal cell of the
collecting duct. Examples include Liddle’s syndrome, with an
activating mutation of epithelial Na channel (ENaC); two
typesofGordon’ssyndrome,withmutationsintworegulatory
kinases [with no lysine (K) serine/threonine protein kinases
(WNK)1 or WNK4]; and apparent mineralocorticoid excess
(AME), with an inactivating mutation in the glucocorticoid-
metabolizing 11β-hydroxysteroid dehydrogenase type 2
enzyme (11HD2). In another group, abnormal adrenal steroid
production leads to inappropriate stimulation of the mineralo-
corticoid receptor (MR) in the distal nephron. The patho-
physiology may involve inappropriate production of
aldosterone [in glucocorticoid-remediable aldosteronism
(GRA) and familial hyperaldosteronism type II (FH II)], of
cortisol (in familial glucocorticoid resistance), or of other
steroid metabolites (in congenital adrenal hyperplasia and
GRA). In contrast to earlier beliefs, hypertension in many of
the inherited disorders may be mild, and electrolyte and acid-
base abnormalities are often not present. Monogenic hyper-
tension should therefore enter the differential diagnosis of any
child or adolescent with hypertension. Plasma renin activity
(PRA) is the appropriate screening tool for all types of
inherited hypertension.
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Abbreviations
11HD2 11β-hydroxysteroid dehydrogenase type
2 enzyme
AME apparent mineralocorticoid excess
DCT distal convoluted tubule
ENaC amiloride-sensitive epithelial Na channel
FH II familial hyperaldosteronism type II
GRA glucocorticoid-remediable aldosteronism
MR mineralocorticoid receptor
NCC thiazide-sensitive NaCl-cotransporter
PC collecting-duct principal cell
PRA plasma renin activity
ROMK renal outer medulla K channel
SGK1 serum- and glucocorticoid-inducible
protein kinase 1
WNK1 and
WNK4
With no lysine (K) serine/threonine
protein kinases
Introduction
It has long been recognized that hypertension in children, in
contrast to adults, is often secondary to a definable
underlying etiology. Pediatricians have been taught to look
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e-mail: vvehas@lsuhsc.edufor primary causes such as kidney disease, renovascular
hypertension, coarctation of the aorta, pheochromocytoma,
hyperthyroidism, and others. Even after the more obvious
causes have been ruled out, there are a few children in whom
secondary hypertension is strongly suspected but the
conventional search for a primary etiology is unsuccessful.
A number of these children have hypertension due to single
gene mutation inherited in Mendelian fashion. Progress in
genetics and molecular biology during the past decade has
greatly advanced our understanding of the pathogenetic
mechanisms of these conditions. Some of these familial
disorders, once considered rare curiosities, are proving to be
common enough to be included in the differential diagnosis
of any hypertensive child. This review discusses the group of
hypertensive disorders caused by a single gene mutation in
which recent research, much of it done in the laboratory of
Richard Lifton at Yale University, has unveiled the mecha-
nism leading to increased blood pressure. Other hereditary
conditions such as familial pheochromocytoma, Williams
syndrome, neurofibromatosis, and polycystic kidney disease
are beyond the scope of this discussion.
Two features are shared by all types of monogenic
hypertension in which the mechanism has been solved.
First, the functional consequence of the abnormal gene in
each case is increased sodium (Na) transport in the distal
nephron. Second, plasma renin activity is invariably sup-
pressed. The inescapable conclusion is that the hyperten-
sion is due to expanded extracellular volume resulting from
inappropriate Na reabsorption by the distal tubule. This
conclusion is consistent with the well-established role of
the distal nephron in physiologic regulation of extracellular
volume and with the hypothesis, initially formulated by
Arthur Guyton, that failure of the renal Na-natriuresis
mechanism to regulate Na and volume balance is part of
any sustained hypertension, including essential hyperten-
sion [1, 2]. Because the unraveling of the cellular
mechanisms of inherited hypertension has led to new
insights into normal physiology of the distal nephron, an
overview of distal nephron Na transport is briefly presented
before the different disorders are discussed.
Na transport in distal nephron
The two main Na-transporting cell types in the distal
nephron are the distal convoluted tubule (DCT) cell and the
majority cell in the collecting duct, the collecting-duct
principal cell (PC). In addition, a transitional cell type may
be present in the late DCT (connecting tubule), with
features of both cell types. The basic configuration of the
two cell types, illustrated in Fig. 1, is similar. The target of
regulation and the rate-limiting step in the transepithelial
Na transport is Na entry down its concentration gradient
into the cell through the apical (luminal) Na transporter. In
the DCT cell, the luminal Na transporter is the thiazide-
sensitive sodium chloride (NaCl) cotransporter (NCC); in
the principal cell, it is the amiloride-sensitive epithelial Na
channel (ENaC). Na is actively extruded from the cell by
the basolateral (contraluminal) sodium-potassium adenosine
triphosphate (Na/K-ATPase), which is responsible for
maintaining the low cytoplasmic Na concentration. K
secretion is accomplished through the renal outer medulla
K channel (ROMK) in the apical membrane, but K
channels are also present in the basolateral membrane.
Under most circumstances, the DCT is believed to exhibit
modest K secretion, whereas K secretion in the collecting
duct can achieve high rates depending on homeostatic
needs. Na absorption from the lumen maintains the lumen-
negative transmembrane potential that contributes to the
driving force for K and proton secretion in the collecting
duct; excessive Na reabsorption may lead to hypokalemia
and metabolic alkalosis.
Regulation of Na transport in the distal nephron is
incompletely understood. The best documented mechanism
is the regulation by mineralocorticoids. Binding of a ligand
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Fig. 1 Simplified diagram of distal nephron sodium (Na)-transporting
cell [distal convoluted tubule (DCT) cell and collecting duct principle
cell (PC)]. The predominant apical Na transporter in the DCT cell is
the thiazide-sensitive sodium chloride cotransporter (NCC) and in the
collecting duct PC amiloride-sensitive epithelial sodium channel
(ENaC), but some overlap exists between the cell types. Both are
shown in the same cell in the diagram. For clarity, other transporters
such as the potassium (K) channels are omitted. A aldosterone, C
cortisol, GR peripheral tissue glucocorticoid receptor. Activation and
suppression are indicated by circled + and circled − , respectively.
Location of mutated proteins is indicated by circled numbers
corresponding to the numbers in the text; red circles denote primary
distal nephron disorders; blue circles denote adrenal and peripheral
glucocorticoid receptor disorders
1930 Pediatr Nephrol (2009) 24:1929–1937(aldosterone) to the mineralocorticoid receptor (MR) in the
target cells leads, via genomic and nongenomic signaling
systems including serum- and glucocorticoid-inducible
protein kinase 1 (SGK1), to increased activity of the apical
Na transporter. The MR itself does not discriminate between
aldosterone and cortisol; the mineralocorticoid-specificity is
conferred by the cytoplasmic 11β-hydroxysteroid dehy-
drogenase type 2 enzyme (11HD2), which rapidly converts
cortisol to inactive metabolites and thus protects the MR
from “illicit” occupation by cortisol. The importance of the
enzyme becomes clear when one considers that the ratio of
aldosterone to cortisol in circulation is 1:100–1,000.
Although traditionally the collecting duct PC has been
considered the target of aldosterone, it is now recognized
that the DCT cell (and the connecting tubule cell) is also
mineralocorticoid responsive [3]. Therefore, Na reabsorp-
tion is under mineralocorticoid control in both the DCT and
the collecting duct.
Recent advances in the molecular biology of Gordon’s
syndrome (see below) have uncovered previously unknown
distal nephron regulatory elements [4, 5]. Two kinases, with
no lysine (K) serine/threonine protein kinase (WNK)1 and
WNK4, expressed in the distal nephron cells, participate in
the regulation of Na and K transport. WNK4 phosphorylates
NCC, which prevents incorporation of the transporter into
the apical membrane. By this mechanism, WNK4 exerts a
tonic baseline suppression on NCC activity, which explains
why interference with WNK4 can lead to augmented Na
transport. WNK1 has no direct effect on NCC, but it
modifies Na transport through inhibition of WNK4. In
addition, WNK1 was recently been shown to activate ENaC
through activation of SGK1 [6]. Moreover, both WNK1 and
WNK4 appear to influence K transport in the DCT and the
collecting duct by mechanisms separate from Na transport
regulation, but the picture is still far from complete [7, 8].
It is clear from the above physiologic considerations that
there is a large number of candidate genes whose mutations
may explain Na transport abnormalities in the distal
nephron. Only those resulting in upregulated transport and
hypertension are discussed below. The known disorders can
be divided into (1) primary disorders of the distal nephron,
and (2) primary adrenal disorders.
Distal nephron disorders
1. Liddle’s syndrome
Collecting-duct Na transport ultimately depends on the
activity of ENaC, which consists of three subunits encoded
for by separate genes. ENaC is also present in the terminal
portion of DCT. Several mutations in the β and γ subunits
have been described that result in increased ENaC-mediated
Na flux [9, 10]. The channel activity is, in part, regulated
by recycling of the transporter between the apical mem-
brane and subapical vesicles. It has been shown that the
mutations truncate or modify the cytoplasmic tail of the
transmembrane protein, deleting the binding site necessary
for the retrieval of the channel for degradation or recycling
[11]. Therefore, the number of functioning channels in the
membrane is increased. In addition, the mutations may
render the membrane-bound subunit proteins susceptible to
proteolytic cleavage, which further enhances the channel
activity by increasing its open probability [12].
As expected for activating mutations, the inheritance
pattern is autosomal dominant. Liddle’s syndrome may be
the most common type of monogenic hypertension, and it
has been reported in many ethnic populations, including
Caucasians, Asians, and blacks. Hypertension frequently
begins in childhood but may be asymptomatic and escape
detection until early adulthood. The presence of hypokale-
mia and mild metabolic alkalosis is variable. Plasma renin
activity (PRA) and plasma aldosterone levels are markedly
suppressed.
Treatment consists primarily of a low-salt diet and an
agent that directly inhibits ENaC, such as amiloride or
triamterene. It is important to recognize that MR antago-
nists are without effect. Strict adherence to low-salt diet
often removes the need for other antihypertensive medi-
cations, but some patients, especially after long-standing
hypertension, may require nonspecific treatment with other
antihypertensives such as calcium (Ca)-channel blockers.
Untreated individuals are at high risk for cardiovascular
morbidity and mortality.
2. Gordon’s syndrome (familial hyperkalemic hypertension,
pseudohypoaldosteronism type II)
The phenotypic features of Gordon’s syndrome are hyper-
kalemia, mild metabolic acidosis, and hypertension. Be-
cause the abnormalities respond to low-dose thiazide
treatment, the syndrome was linked to abnormal function
of the thiazide-sensitive nephron segment, the DCT, long
before any gene mutations were discovered. It is now clear
that mutations in at least four different genes may cause
Gordon’s syndrome, although only two have been identi-
fied. In contrast to expectations, no activating mutations in
the NCC itself have been found despite the clinical
evidence that Na reabsorption in DCT is increased. Instead,
mutations in the newly discovered kinases WNK1 and
WNK4 have been reported in some patients, and further
research has revealed the likely underlying mechanisms [4,
5, 8]. The culprit in some families is an inactivating
mutation in WNK4 that releases NCC from the tonic
suppression by WNK4, leading to constitutively increased
Na reabsorption in DCT (Fig. 1). In contrast, in regard to
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activity of WNK4, further enhancing the suppressive effect
of WNK4 on ROMK and explaining the hyperkalemia [7].
In the second type of Gordon’s syndrome, a large
intronic mutation causes an increase in WNK1 expression.
Because the indirect physiologic effect of WNK1 on NCC
is activation (Fig. 1), the mutation causes upregulation of
Na transport [4, 5]. WNK1 may also activate ENaC via
SGK1 [6]. The recent demonstration of two different
WNK1 isoforms in the kidney, with opposing effects on
ROMK, complicates the understanding of the K retention in
WNK1 mutations [8]. At least two additional monogenic
types of Gordon’s syndrome, apparently not involving
WNK kinases, have been described, but the underlying
gene defects are unknown [13, 14].
Gordon’s syndrome is inherited as an autosomal domi-
nant trait. This is unusual but not unique for a loss-of-
function mutation such as the WNK4 mutation. There are
other examples of loss-of-function in one allele resulting in
disease. Whether the clinical features differ between
different genotypes of Gordon’s syndrome is unknown.
The metabolic abnormalities hyperkalemia and hyper-
chloremic metabolic acidosis tend to precede the onset of
hypertension, and hypertension often does not manifest
until adult life [15, 16]. In fact, Spitzer-Weinstein syndrome
in children, consisting of hyperkalemia, metabolic acidosis,
and growth failure but not hypertension, is now believed to
be an early presentation of Gordon’s syndrome [7, 17–19].
Thus, the presentation may resemble that of type IV renal
tubular acidosis.
Diagnostic features, in addition to hyperkalemia and
acidosis, include suppression of plasma renin activity and
normal or high aldosterone level. The high aldosterone
level is explainable by direct stimulation of aldosterone
secretion by high plasma K levels despite the increase in
extracellular volume. Plasma K and acid-base status are not
invariably abnormal. Glomerular filtration rate is normal in
contrast to many forms of type IV renal tubular acidosis.
Hypercalciuria is present in many if not all patients with
Gordon’s syndrome [16, 20]. Both hypertension and
metabolic abnormalities typically respond to low-dose
thiazide diuretics.
3. Apparent mineralocorticoid excess (AME)
Apparent mineralocorticoid excess (AME) is a rare auto-
somal recessive disorder consisting of an inactivating
mutation of the 11HD2 enzyme [21]. This allows cortisol
to occupy and activate the MR (Fig. 1). The typical features
are unregulated stimulation of Na reabsorption, K secretion,
and hydrogen (H) secretion. This is accompanied by renal
concentrating defect, most likely due to chronic hypokale-
mia, and sometimes by hypercalciuria and nephrocalci-
nosis, the mechanisms of which is unclear [22]. As a result
of lack of 11HD2 activity, the conversion of cortisol to
cortisone is impaired, resulting in an abnormal ratio of
cortisol metabolites [such as tetrahydrocortisol (THF) and
allotetrahydrocortisol (5αTHF)] to cortisone metabolites
[such as tetrahydrocortisone (THE)] in the urine.
AME has been reported from all parts of the world and in
many ethnic groups, including Caucasians, blacks, Asians,
and American Indians. The disease was earlier believed to
invariablypresent inearlychildhood,witha severephenotype
including low birth weight, failure to thrive, and hypokalemic
metabolic alkalosis. These patients frequently exhibit end-
organ damage in the heart, the retina, and the central nervous
system, and the mortality rateinuntreatedpatientsishigh[23,
24]. More recently, however, milder phenotypes have been
described, some presenting with hypertension in adulthood
without electrolyte abnormalities [22, 25, 26]. The milder
phenotypes are associated with mutations causing only
partial inactivation of 11HD2 [22, 26].
Diagnosis should be suspected in any low renin, low
aldosterone hypertension with signs of mineralocorticoid
excess. Traditionally, the diagnosis has been confirmed by
urine steroid profile, especially by the ratio of THF +
5αTHF to THE in a 24-h urine collection. However, in
patients with mild disease, the ratio may not be abnormal,
making diagnosis difficult except by genetic testing.
MR antagonists, K supplementation, and dietary Na
restriction are the mainstay of treatment of AME. The more
specific MR antagonist eplerenone, instead of spironolac-
tone, can be used to minimize side effects. In addition,
amiloride may be added to help conserve K. Thiazide
diuretics have been used to ameliorate hypercalciuria.
4. Hypertension exacerbated by pregnancy
Geller and coworkers recently described a new genetic
hypertension disorder called “hypertension exacerbated by
pregnancy” [27]. The term is slightly misleading because the
disorder is not limited to females; in fact, the proband was a
15-year-old male. The affected individuals have an activating
mutation of MR, resulting in constitutively stimulated Na
reabsorption (Fig. 1). Hypertension is present in nonpregnant
patients and may be severe, but the characteristic feature is
marked worsening during pregnancy. The proposed expla-
nation is that the mutation renders the receptor sensitive to
nonmineralocorticoid steroids such as progesterone, the level
of which rises 100-fold during pregnancy. Notably, the
mutated receptor can also be activated by spironolactone.
The inheritance pattern is autosomal dominant. The
disorder is mostly of theoretical interest, because the
estimated frequency of the precise mutation required for
intrinsic receptor activation is so low that, at most, a few
pedigrees are predicted to exist (D. Geller, personal
1932 Pediatr Nephrol (2009) 24:1929–1937communication). Treatment consists of salt restriction and
thiazide diuretics or ENaC antagonists; MR receptor
antagonists are contraindicated.
Adrenal disorders
1. Glucocorticoid-remediable aldosteronism [(GRA)
familial hyperaldosteronism type I]
The adrenal cortex synthesizes aldosterone in the zona
glomerulosa under the control of angiotensin II and cortisol
in the zona fasciculata under the control of the adrenocor-
ticotropic hormone (ACTH). The key enzymes in the
synthetic pathways are aldosterone synthase and 11β-
hydroxylase, respectively. The corresponding genes lie
adjacent to each other on chromosome 8. GRA is the result
of unequal crossing over between the two genes. The
hybrid gene possesses an ACTH-responsive promoter
element and an aldosterone synthase coding region, result-
ing in ACTH-stimulated aldosterone production, indepen-
dently of renin and of Na balance requirements [28–30]. In
addition, two other steroids with mineralocorticoid activity,
18-oxocortisol and 18-hydroxycortisol, are produced from
cortisol in the zona fasciculata by aldosterone synthase in
GRA. The high levels of circulating mineralocorticoids
activate distal nephron MR and upregulate Na reabsorption
and K secretion.
The inheritance pattern of GRA is autosomal dominant.
Different pedigrees exhibit different crossover patterns of
the hybrid gene, suggesting that the mutations arose
independently in each pedigree [31]. Notably, GRA has
not been found in blacks.
Most affected individuals develop hypertension during
childhood or even in infancy [5] and exhibit significant
cardiovascular morbidity [32, 33], but milder phenotypes
and even normotension have been described [31, 32, 34]. A
number of patients have been first diagnosed with hyper-
tension in adolescence [35]. Phenotype severity may vary
within the same family. GRA patients appear to be
particularly at risk for cerebral aneurysms and intracranial
bleeding, and magnetic resonance angiographic (MRA)
screening beginning at puberty has been recommended
[36].
Mild hypokalemia is present in less than half of affected
individuals, and a few exhibit mild metabolic alkalosis [31,
32, 35]. PRA is suppressed, but plasma aldosterone
concentration is not always outside the reference range.
Ratio of plasma aldosterone (ng/dl) to plasma renin activity
(ng/ml/h) of over 30 (normal<20) is highly suggestive of
primary aldosteronism. Dexamethasone suppression test,
urine steroid profiles (increased 18-oxocortisol), adrenal
imaging, and adrenal-vein sampling have traditionally been
used to distinguish GRA from other types of primary
aldosteronism, but the availability of reliable genetic testing
for the chimeric gene has eliminated the need for more
cumbersome evaluation.
Treatment of GRA consists of glucocorticoids to
suppress ACTH-stimulated mineralocorticoid production
and/or of MR antagonists. Conventional high-dose gluco-
corticoid treatment is unnecessary. It is now clear that blood
pressure can be controlled without total normalization of
biochemical parameters using low-dose treatment. For
adults, dexamethasone dose of 0.125–0.24 mg daily or
prednisolone dose of 2.5–5 mg daily appears sufficient
[33]. MR antagonist treatment is an alternative, either alone
or in combination with low-dose glucocorticoid. The ENaC
antagonists amiloride or triamterene can be used as an
adjunctive therapy.
2. Familial hyperaldosteronism type II (FH II)
Familial hyperaldosteronism type II (FH II) is similar to
GRA (FH I) in that excess mineralocorticoid production is
responsible for the development of hypertension, but the
hypertension is not suppressible by dexamethasone. Auto-
somal dominant inheritance suggests that FH II is due to a
single gene mutation and, although the gene has not been
identified, the locus has recently been narrowed to a band
on chromosome 7 [37]. Many patients with FH II have a
family history of adrenal hyperplasia or adenoma, which
suggests that a growth factor may be involved.
Widened criteria for screening have revealed FH II to be
more common than previously believed, and it may be the
most common inherited type of hypertension in adults [38].
However, although renin-aldosterone abnormalities have
been reported in affected adolescents [39], hypertension
due to FH II typically does not manifest until adulthood.
FH II is clinically and biochemically indistinguishable from
noninherited primary aldosteronism, and currently, the
diagnosis can be only confirmed by positive family history
until genetic detection is available.
3. Congenital adrenal hyperplasia
In two subtypes of congenital adrenal hyperplasia, there is
excessive accumulation of intermediate products with
mineralocorticoid activity. Defects in 11-hydroxylase and
17-hydroxylase result in overproduction of 21-hydroxylated
steroids, which activate MR. In addition to having other
endocrine manifestations such as genital ambiguity, these
patients are hypertensive due to Na retention mediated by
the distal nephron. The diagnosis is made by clinical
presentation and by analysis of plasma or urine steroid
profiles. The hypertension responds to treatment with an
MR antagonist. Note that the most common type of
Pediatr Nephrol (2009) 24:1929–1937 1933congenital adrenal hyperplasia, 21-hydroxylase deficiency,
is an Na-losing state and does not cause hypertension.
4. Familial glucocorticoid resistance
High cortisol availability may overwhelm the capacity of
the 11HD2 enzyme to metabolize it, leading to activation of
the MR by cortisol and to excessive Na reabsorption in the
distal nephron. This is the case in families with an inherited
defect in the glucocorticoid receptor, rendering it partially
unresponsive to cortisol and with consequent feedback
overproduction of cortisol and androgens [40]. Inheritance
pattern differs between different mutations [41]. The
severity of associated features and the presence of hyper-
tension depend on the degree of receptor impairment.
Mutations causing complete receptor inactivation are not
compatible with life. Because of the glucocorticoid resis-
tance, the patients are not Cushingoid. Diagnosis of this
rare disorder rests of documentation of markedly elevated
plasma cortisol levels. The hypertension responds to MR
blockade.
Evaluation for inherited hypertension
When should a child be evaluated for possible inherited
hypertension? Although the true prevalence of this group of
disorders is not known, many of them, such as Liddle’s
syndrome, are more common than previously suspected.
Inheritance pattern, if clear, may provide clues (Table 1),
but family history is often misleading because of the high
prevalence of essential hypertension in adults and even
adolescents. The conventional wisdom that hereditary
conditions should be considered in children with severe
hypertension or electrolyte abnormalities is only partially
true. Whereas a child with severe hypertension is more
likely to have one of the inherited disorders, it is now clear
that many individuals with inherited hypertension have
only mild to moderate hypertension, and electrolyte
abnormalities may be absent (Table 1).
Hyperkalemia is frequently but not always present in
Gordon’s syndrome; hypokalemia is present in less than
50% of GRA and often but not consistently present in AME
and Liddle’s syndrome. Mild metabolic alkalosis may
infrequently accompany all except Gordon’s syndrome,
which is associated with metabolic acidosis. Importantly,
because all patients must eventually develop a neutral,
steady-state electrolyte balance despite initial expansion of
extracellular volume, urine Na and K excretion cannot be
used for diagnosis. Therefore, whereas clinical presentation
and routine electrolyte values may raise a suspicion of
inherited hypertension, they cannot be relied on to rule out
these disorders.
An easy and useful screening tool is PRA, the inclusion
of which in the initial evaluation of all hypertensive children
is justified. This is preferably done before treatment because
antihypertensive drugs may alter renin secretion. Because
extracellular volume is expanded, resulting in suppression
of the renin–angiotensin system in all of the disorders
discussed in this review, they all share the feature of
suppressed PRA. Ideally, PRA should be correlated with
Na intake (measurable as 24-h Na excretion), but a random
renin level is usually informative. If suppressed plasma
renin activity is documented, the next step is to measure
plasma aldosterone if not done initially. Suppressed plasma
aldosterone is present in all inherited hypertension except
primary aldosteronism (GRA, FH II) and Gordon’s syn-
drome and should therefore lead to a strong suspicion of
AME or Liddle’s syndrome. In primary aldosteronism, the
most discriminating test is the ratio of plasma aldosterone
(ng/dl) to plasma renin activity (ng/ml/h); a value of greater
that 30 indicates primary aldosteronism (Table 1).
Table 1 Features of inherited hypertension
Inheritance pattern Age K PRA Aldo Aldo:PRA GC resp. MR-A resp. Rx
Liddle’s AD C,A N or ↓↓ ↓ –– A,Tr
Gordon’s AD A (C) N or ↑↓ No r↑↑ –– T
AME AR I,C,A ↓ (N) ↓↓ – + MR-A
H-P AD C,A N or ↓↓ ↓ – reversed A,Tr,T
GRA AD I,C N or ↓↓ ↑ (N) ↑ + + G,A,Tr
FH II AD A N or ↓↓ ↑ ↑ – + MR-A
CAH AR I N or ↓↓ ↓ – + MR-A
FGR AR/AD I N or ↓↓ ↓ – + MR-A
AME apparent mineralocorticoid excess, H-P hypertension exacerbated by pregnancy, GRA glucocorticoid-remediable aldosteronism, FH II
familial hyperaldosteronism type II, CAH congenital adrenal hyperplasia with 11- or 17-hydroxylase deficiency, FGR familial glucocorticoid
resistance, AD autosomal dominant, AR autosomal recessive, Age typical age at presentation, I infancy, C childhood, A adulthood, K potassium,
N normal, ↓ decreased, ↑ increased, PRA plasma renin activity, Aldo aldosterone, Aldo:PRA ratio of aldosterone to PRA (>30 diagnostic if Aldo.
in ng/dl, PRA in ng/ml/h), GC resp. response to glucocorticoids, – negative, + positive, MR-A resp. response to mineralocorticoid receptor
antagonists, Rx treatment, A amiloride, Tr triamterene, T thiazides
1934 Pediatr Nephrol (2009) 24:1929–1937Genetic testing for the mutations causing hereditary
hypertension is increasingly becoming available. Information
on testing for clinical purposes can be found at www.
genetests.org. Final confirmation of GRA can nowadays
reliably be made by direct documentation of the presence of
the hybrid gene by Southern blotting instead of the
traditional dexamethasone suppression test. However, in
most of the other disorders, testing is based on direct DNA
sequencing or on probing for known mutations and will not
be able to detect previously unreported mutations. In some
patients, only a presumptive diagnosis can be made based on
clinical presentation, laboratory findings, and response to
specific pharmacologic agents.
Questions:
(Answers appear following the reference list.)
1. A 20-year-old woman presents with headache and blood
pressure of 185/100. She is on no medications. Her
mother and 25-year-old brother have hypertension.
Metabolic panel shows Na 142, Cl 115, K 5.6, CO2 17.
The treatment most likely to control her hypertension is:
(1) Ca-channel blocker
(2) Spironolactone
(3) Hydrochlorothiazide
(4) Amiloride
(5) Furosemide
2. A 3-year-old Caucasian boy is evaluated for hyperten-
sion. He has a 7-year-old brother with hypertension
whose disease is poorly controlled with the combina-
tion of enalapril and nifedipine. The patient has normal
electrolytes, plasma renin activity of 0.5 ng/ml per hour
(normal for age 3.0–9.0), and plasma aldosterone
concentration of 30 ng/dl (normal 3–35). The most
likely diagnosis is:
(1) Liddle’s syndrome
(2) Gordon’s syndrome
(3) Renal artery stenosis
(4) Glucocorticoid-remediable aldosteronism
(5) Familial aldosteronism type II
3. A2-year-oldboyisreferredforfailuretothrive.Hisblood
pressure is 145/95. Laboratory evaluation shows Na 139,
K3 . 0 ,C l9 0 ,C O 2 35, and plasma renin activity<0.2 ng/
ml/ per hour Renal ultrasound shows bilateral nephro-
calcinosis. The most appropriate initial drug to treat
hypertension is:
(1) Enalapril
(2) Spironolactone
(3) Hydrochlorothiazide
(4) Furosemide
(5) Aldosterone
4. Genetic testing can exclude the following conditions:
(1) Liddle’s syndrome
(2) Gordon’s syndrome
(3) Glucocorticoid-remediable aldosteronism
(4) Familial hyperaldosteronism type II
(5) Apparent mineralocorticoid excess syndrome
5. Inherited hypertension can be ruled out in a hyperten-
sive 17-year-old if:
(1) He was normotensive at age 12
(2) His maximum blood pressure does not exceed
140/85
(3) His plasma renin activity is low
(4) His plasma renin activity is normal
(5) His plasma aldosterone concentration is normal
6. Which of the following treatments is not effective:
(1) Hydrochlorothiazide for Gordon’s syndrome
(2) Amiloride for Liddle’s syndrome
(3) Spironolactone for apparent mineralocorticoid excess
(4) Amiloride for apparent mineralocorticoid excess
(5) Spironolactone for Liddle’s syndrome
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